Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort
Rattachement africain : dk. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION AND OBJECTIVES: Risk stratification is important in the management of metabolic dysfunction-associated steatotic liver disease (MASLD) to prioritize monitoring and treatment resources. We evaluated whether non-invasive tests (NITs) can predict major adverse liver outcomes (MALOs) and diagnose advanced fibrosis in patients with MASLD. PATIENTS AND METHODS: A prospective cohort of 270 patients with MASLD (median age 56 years; 44% female; 41% type 2 diabetes) was evaluated using nine NITs: FIB-4, LSM, Agile3+, Agile4, FAST, ADAPT, ELF, PROC3, and C1M. Cox proportional hazards models and ROC analyses were used to assess prognostic performance for MALOs and diagnosis of advanced fibrosis, respectively. RESULTS: Over a four-year follow-up period, 25 patients experienced MALOs. All NITs were associated with MALOs, though confidence intervals were wide given the limited number of events. Most NITs demonstrated positive associations with risk (HR range 1.82-5.39; p < 0.05), whereas C1M was inversely associated (HR 0.63, 95% CI 0.49-0.82; p < 0.001), indicating reduced risk. As a secondary objective, we evaluated whether each NIT could diagnose advanced fibrosis. FIB-4 and LSM effectively ruled out advanced fibrosis, while ELF and the Agile scores showed the strongest overall discriminative performance. For confirming advanced fibrosis, ELF (81%/76%) and Agile3+ (85%/79%) achieved the best sensitivity-specificity balance. CONCLUSIONS: Our findings suggest that NITs may hold both diagnostic and prognostic value, helping to identify advanced fibrosis and stratify future risk of MALOs in MASLD which is a clinically heterogenous but clinically relevant outcome. Additional research is needed to evaluate their performance in primary care settings. IMPACT AND IMPLICATIONS: In MASLD, NITs have the potential for identification of at-risk patients. Identifying NITs that predict beneficial as well as detrimental outcomes could also add value to monitoring strategies although further evidence is needed to evaluate this potential.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Investigation of non-invasive tests for fibrosis diagnosis and prognostication of events in metabolic dysfunction-associated steatotic liver disease: A prospective study cohort
- Date Crossref
- 01/09/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Novo Nordisk Foundation pays non établi dans la noticeStructure de recherche
-
Novo Nordisk (Denmark) pays non établi dans la noticeEntreprise
-
Hvidovre Hospital pays non établi dans la noticeÉtablissement de santé
-
Nordic Bioscience (Denmark) pays non établi dans la noticeEntreprise
-
Faculty of Health and Medical Sciences Novo Nordisk Foundation Center for Protein Research pays non établi dans la noticeUniversité ou école supérieure
-
Novo Nordisk A/S pays non établi dans la noticeInstitution
-
Copenhagen University Hospital Hvidovre Gastro Unit pays non établi dans la noticeUniversité ou école supérieure
-
Nordic Bioscience A/S pays non établi dans la noticeInstitution
Novo Nordisk Foundation, Novo Nordisk (Denmark) et Hvidovre Hospital, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.